Nureca Ltd

Nureca Ltd

$NURECAMedical Equipment & SuppliesNSEBSE

Nureca Ltd (NURECA) last traded at ₹295, a market capitalisation of ₹281 crore, on a P/E of 64.9. Over the past 52 weeks the stock has ranged between ₹200 and ₹358. Nureca Ltd last reported results for the quarter ended Jun 2026, with sales of ₹40.34 crore and net profit of ₹3.07 crore. Figures are as of 25 Aug 2026 and are not real time.

Nureca Ltd share price and key metrics

Current price
₹295
Market cap
₹281 cr
Stock P/E
64.9
Book value
₹189
ROE
1.12%
ROCE
3.30%
Dividend yield
0.00%
52w high / low
358/200

Metrics as of 25 Aug 2026. Not real time.

Nureca Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹40.34 cr, up 18.0% from ₹34.18 cr a year earlier. Net profit was ₹3.07 cr, up 279.0% year on year.

Nureca Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales31.1926.4631.7434.1837.7439.6435.4140.34
Expenses33.5430.4730.5434.7434.4736.3941.1936.92
Operating profit-2.35-4.011.2-0.563.273.25-5.783.42
OPM %-7.53%-15.15%3.78%-1.64%8.66%8.20%-16.32%8.48%
Other income3.171.481.992.572.322.191.021.82
Interest0.270.180.620.250.460.280.30.2
Depreciation0.620.540.520.530.540.50.450.61
Profit before tax-0.07-3.252.051.234.594.66-5.514.43
Tax %585.71%-13.85%-20.00%34.15%21.13%19.96%10.71%30.93%
Net profit-0.48-2.82.470.813.633.73-6.093.07
EPS (₹)-0.48-2.802.470.813.633.91-6.383.22

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Nureca Ltd annual results

Nureca Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales21325611192110147153
Operating profit6256-15-10-804
OPM %29%22%-13%-11%-7%0.1%2.7%
Net profit4645-8-2124
EPS (₹)46.3744.96-8.25-1.790.852.184.38

TTM is the trailing twelve months to the most recent quarter.

Nureca Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
-7%
3 Years
10%
TTM
24%
Compounded Profit Growth
10 Years
%
5 Years
-46%
3 Years
30%
TTM
176%
Stock Price CAGR
10 Years
%
5 Years
-28%
3 Years
-3%
1 Year
26%
Return on Equity
10 Years
%
5 Years
3%
3 Years
-1%
Last Year
1%

Nureca Ltd shareholding pattern

Promoters held 68.09% at Jun 2026, up from 64.33% at Jun 2025. FIIs 0.11% and DIIs 0.24%.

Nureca Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters63.78%64.06%64.30%64.33%64.97%64.97%68.09%68.09%
FIIs0.69%0.36%1.07%0.07%0.07%0.08%0.28%0.11%
DIIs0.00%0.04%0.04%0.04%0.04%0.04%0.24%0.24%
Public35.53%35.54%34.59%35.56%34.92%34.91%31.39%31.57%
No. of shareholders41,98641,31439,30438,07537,46835,80134,55833,979

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

Nureca Ltd corporate filings

  • Disclosure under Regulation 7(2) of Securities and Exchange Board of India (Prohibition of Insider Trading )Regulations ,2015 (PIT Regulations )Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Nureca Ltd has filed a disclosure under Regulation 7(2) of the SEBI (Prohibition of…

    Read the full analysis
  • Additional details required for Corporate Announcement under Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Nureca Ltd has been directed by the exchange to provide additional details regarding a…

    Read the full analysis
  • Pendency of Litigation(s)/disput(s) or the outcome impacting the Company.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Nureca Ltd has filed a disclosure regarding the status of pending litigation or disputes…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Nureca Ltd

Cruxal reads every Nureca Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.